Regeneron says its Covid-19 treatment reduces viral levels, improves symptoms

REGN-COV2 is part of a class of biotech therapies known as monoclonal antibodies. Several companies are using the technology to manufacture copies of human antibodies to the new coronavirus.
Trial results for the first 275 patients showed the greatest effect in those who had not yet mounted their own immune response prior to treatment.(Bloomberg)
Trial results for the first 275 patients showed the greatest effect in those who had not yet mounted their own immune response prior to treatment.(Bloomberg)
Published on Sep 30, 2020 05:23 AM IST
Copy Link
Reuters | ByReuters| Posted by Susmita Pakrasi

Regeneron Pharmaceuticals Inc on Tuesday said its experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized Covid-19 patients, enhancing its chances of becoming a treatment for the disease that has killed over a million people worldwide.

“We hope these data will support an EUA” (emergency use authorization) from the U.S. Food and Drug Administration, Regeneron Chief Scientific Officer George Yancopoulos said on a conference call.

The FDA can authorize emergency use of a drug before completing its review for a formal approval.

Shares of Regeneron, which closed at $573.61, were halted after hours.

Trial results for the first 275 patients showed the greatest effect in those who had not yet mounted their own immune response prior to treatment. That suggests the treatment, REGN-COV2, could help patients whose own immune system is not strong enough to combat the virus, Regeneron said.

REGN-COV2 is part of a class of biotech therapies known as monoclonal antibodies. Several companies are using the technology to manufacture copies of human antibodies to the new coronavirus.

Regeneron believes its dual-antibody formula will limit the ability of the virus to escape detection and attack.

The study tested two different doses of REGN-COV2 in two patient populations: those who had mounted an effective immune response on their own (seropositive), and those whose immune response was not yet adequate, or seronegative.

Among patients given a placebo, those who already had effective natural antibodies had a median time to alleviation of symptoms of 7 days, compared to 13 days for seronegative patients.

Among seronegative patients given the Regeneron cocktail, median time to symptom alleviation was 8 days for the high-dose group, and 6 days for the low-dose group.

Regeneron also said REGN-COV2 rapidly reduced viral load through day 7 in seronegative patients. In addition, patients with higher virus levels at the start of the trial had correspondingly greater reductions in viral load with REGN-COV2, which is given by intravenous infusion.

Serious adverse side effects occurred in two placebo patients and one patient who got the lower dose of REGN-COV2. There were no deaths in the trial.

The treatment is also being studied for use in hospitalized patients, and for prevention of infection in people who have been exposed to Covid-19.

The U.S. government in June awarded Regeneron a $450 million supply contract for the antibody cocktail.

Swiss drugmaker Roche Holding AG last month agreed to boost overall manufacturing capacity for REGN-COV2 by at least three and a half times. Under the deal, Regeneron would handle U.S. sales of the treatment and Roche would be responsible for the rest of the world.

SHARE THIS ARTICLE ON
Close Story
QUICKREADS

Less time to read?

Try Quickreads

  • An Air Canada plane is seen in the air after departing from Pearson International Airport in Toronto, Ontario, Canada, on Monday. (REUTERS)

    India’s missions in Canada reach out to students after spate of incidents

    India's missions in Canada are enhancing their outreach to students from India as their numbers balloon along with a spate of incidents, including accidents, suicides, even murders. The latest such tragedy was reported on Sunday, when Peel Regional Police found the body of 20-year-old Navkiran Singh from Moga district in Punjab drowned in the Credit Valley River in Brampton in the Greater Toronto Area. No cause has yet been attributed for the death.

  • Sri Lankan President Gotabaya Rajapaksa.

    Sri Lankan Parl defeats no-confidence motion by Oppn against President Gotabaya

    A no-confidence motion tabled by the Opposition against Sri Lankan President Gotabaya Rajapaksa was defeated in Parliament on Tuesday, media reports said. The motion by Opposition Tamil National Alliance MP M A Sumanthiran to suspend Parliament's standing orders in order to debate an expression of displeasure over President Rajapaksa was defeated with 119 MPs voting against it, the Economy Next newspaper reported. Only 68 MPs voted in favour of the motion, it said.

  • Experts say that India’s decision, coupled with the Ukraine war will create a serious problem globally.

    US envoy urges India to ‘reconsider’ wheat export ban: ‘Will worsen...’

    The United States hopes “India would reconsider” its decision to ban wheat exports which “will make the current global food shortage even worse”, an envoy said on Monday amid concerns with no end in sight for the Ukraine war. Agriculture ministers from the Group of Seven nations on Saturday also emphasised that India's decision to ban wheat exports would worsen the global food shortage.

  • Flags flutter in the wind outside Nato headquarters in Brussels, Belgium. (AP)

    Canada to quickly ratify membership of Finland, Sweden in Nato: Melanie Joly

    Canada will quickly ratify the membership of Finland and Sweden in the North Atlantic Treaty Organisation (Nato), as and when it has been approved. Speaking to reporters during the course of a teleconference from Brussels, Canada's Minister of Foreign Affairs Melanie Joly said such ratification has support from across party lines in Canada.

  • A market shelled by Russia in Chenihiv, on March 30. (AP Photo/Vladislav Savenok)

    Russia was prepared to use artillery against inhabited areas in Chernihiv: UK

    The United Kingdom on Tuesday accused Russia of being prepared for artillery use against inhabited civilian areas in Chernihiv, to the north of Ukraine's Capital, Kyiv, pointing to what it said was the 'scale of damage' to residential buildings caused by Moscow's troops in the region. The UK also projected that Moscow, in a bid to regain momentum in its advance in the Donbas area, would keep relying 'heavily' on massed artillery strikes.

SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, May 17, 2022